Koios Medical and iCAD Partner to Expand AI-Powered, Multi-Modality Breast Cancer Detection Solutions at ECR 2025
iCAD (NASDAQ: ICAD) and Koios Medical have announced a strategic reseller partnership to deliver an integrated AI-powered breast cancer detection solution. The collaboration combines iCAD's ProFound AI® Breast Health Suite for mammography with Koios SmartUltrasound™, creating a comprehensive multi-modality AI suite.
The partnership aims to streamline AI implementation across both mammography and breast ultrasound, providing radiologists with an enhanced workflow from screening to diagnosis. Koios SmartUltrasound is an AI-based platform designed to detect and diagnose thyroid and breast cancers in ultrasound exams, improving interpretation speed and reducing unnecessary surgical procedures.
Both companies will showcase their integrated solution at ECR 2025 in Vienna, Austria, from February 26 to March 2, 2025.
iCAD (NASDAQ: ICAD) e Koios Medical hanno annunciato una partnership strategica per la rivendita di una soluzione integrata per la rilevazione del cancro al seno supportata dall'IA. La collaborazione unisce la ProFound AI® Breast Health Suite di iCAD per la mammografia con Koios SmartUltrasound™, creando una suite AI multi-modale completa.
La partnership mira a semplificare l'implementazione dell'IA sia nella mammografia che nell'ecografia mammaria, fornendo ai radiologi un flusso di lavoro migliorato dalla screening alla diagnosi. Koios SmartUltrasound è una piattaforma basata sull'IA progettata per rilevare e diagnosticare il cancro alla tiroide e al seno durante gli esami ecografici, migliorando la velocità di interpretazione e riducendo le procedure chirurgiche non necessarie.
Entrambe le aziende presenteranno la loro soluzione integrata all'ECR 2025 a Vienna, Austria, dal 26 febbraio al 2 marzo 2025.
iCAD (NASDAQ: ICAD) y Koios Medical han anunciado una asociación estratégica de reventa para ofrecer una solución integrada de detección de cáncer de mama impulsada por IA. La colaboración combina la ProFound AI® Breast Health Suite de iCAD para mamografía con Koios SmartUltrasound™, creando un conjunto integral de IA multimodal.
La asociación tiene como objetivo agilizar la implementación de IA en mamografía y ecografía mamaria, proporcionando a los radiólogos un flujo de trabajo mejorado desde la detección hasta el diagnóstico. Koios SmartUltrasound es una plataforma basada en IA diseñada para detectar y diagnosticar cánceres de tiroides y de mama en exámenes de ecografía, mejorando la velocidad de interpretación y reduciendo procedimientos quirúrgicos innecesarios.
Ambas empresas mostrarán su solución integrada en el ECR 2025 en Viena, Austria, del 26 de febrero al 2 de marzo de 2025.
iCAD (NASDAQ: ICAD)와 Koios Medical는 AI 기반의 유방암 탐지 솔루션을 제공하기 위한 전략적 리셀러 파트너십을 발표했습니다. 이 협력은 iCAD의 ProFound AI® 유방 건강 스위트와 Koios SmartUltrasound™를 결합하여 포괄적인 다중 모드 AI 스위트를 만듭니다.
이 파트너십은 유방촬영술과 유방 초음파 전반에 걸쳐 AI 구현을 간소화하여 방사선과 의사들에게 스크리닝부터 진단까지 향상된 작업 흐름을 제공합니다. Koios SmartUltrasound는 초음파 검사에서 갑상선 및 유방암을 탐지하고 진단하도록 설계된 AI 기반 플랫폼으로, 해석 속도를 개선하고 불필요한 수술 절차를 줄입니다.
양사는 2025년 2월 26일부터 3월 2일까지 오스트리아 비엔나에서 열리는 ECR 2025에서 통합 솔루션을 선보일 예정입니다.
iCAD (NASDAQ: ICAD) et Koios Medical ont annoncé un partenariat stratégique de revente pour proposer une solution intégrée de détection du cancer du sein alimentée par l'IA. Cette collaboration associe la ProFound AI® Breast Health Suite d'iCAD pour la mammographie avec Koios SmartUltrasound™, créant ainsi une suite IA multimodale complète.
Le partenariat vise à rationaliser la mise en œuvre de l'IA à la fois dans la mammographie et l'échographie mammaire, offrant aux radiologues un flux de travail amélioré de la détection au diagnostic. Koios SmartUltrasound est une plateforme basée sur l'IA conçue pour détecter et diagnostiquer les cancers de la thyroïde et du sein lors des examens échographiques, améliorant la rapidité d'interprétation et réduisant les interventions chirurgicales inutiles.
Les deux entreprises présenteront leur solution intégrée lors de l'ECR 2025 à Vienne, en Autriche, du 26 février au 2 mars 2025.
iCAD (NASDAQ: ICAD) und Koios Medical haben eine strategische Wiederverkäuferpartnerschaft angekündigt, um eine integrierte, KI-gestützte Lösung zur Erkennung von Brustkrebs anzubieten. Die Zusammenarbeit kombiniert iCADs ProFound AI® Breast Health Suite für die Mammographie mit Koios SmartUltrasound™, wodurch ein umfassendes, multimodales KI-Paket entsteht.
Das Ziel der Partnerschaft ist es, die Implementierung von KI in der Mammographie und Brustultraschall zu optimieren und Radiologen einen verbesserten Workflow von der Screening-Phase bis zur Diagnose zu bieten. Koios SmartUltrasound ist eine KI-basierte Plattform, die entwickelt wurde, um Schilddrüsen- und Brustkrebs in Ultraschalluntersuchungen zu erkennen und zu diagnostizieren, die Interpretationsgeschwindigkeit zu verbessern und unnötige chirurgische Eingriffe zu reduzieren.
Beide Unternehmen werden ihre integrierte Lösung auf der ECR 2025 in Wien, Österreich, vom 26. Februar bis 2. März 2025 präsentieren.
- Strategic partnership expands iCAD's product offering into ultrasound AI solutions
- Enhanced diagnostic capabilities for dense breast tissue patients
- Potential for increased market penetration through comprehensive AI suite
- None.
NASHUA, N.H. and CHICAGO, Feb. 26, 2025 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD) a global leader in clinically proven AI-powered cancer detection solutions, and Koios Medical, a leader in AI-driven ultrasound cancer diagnosis, today announced a strategic reseller partnership to deliver a comprehensive, multi-modality AI suite for breast cancer detection. This collaboration integrates iCAD’s ProFound AI® Breast Health Suite for mammography with Koios SmartUltrasound™, providing radiologists with an AI-powered pathway from screening to diagnosis.
“iCAD has long been a leader, the pioneer in AI for breast imaging. It is an honor to collaborate with a company with an unmatched track record of improving clinical outcomes for patients and a rich history of innovation,” said Chad McClennan, President & CEO of Koios Medical, Inc.
The partnership reflects the rapidly growing adoption of best-in-class AI solutions across breast imaging facilities. “Our collaboration with iCAD is ultimately a customer-driven initiative. Breast imaging radiologists have long embraced innovation and are rapidly adopting best-of-breed AI solutions. Physicians seek accuracy, efficiency, and peace of mind. By offering an integrated ‘breast AI suite’ that includes both iCAD’s ProFound AI and Koios SmartUltrasound, we’re enabling a more comprehensive, AI-enhanced patient pathway. Streamlining AI acquisition and implementation across both mammography and breast ultrasound is a logical and necessary step forward,” said Chad McClennan, President & CEO of Koios Medical, Inc.
Dana Brown, President and CEO of iCAD, added, “This partnership reinforces iCAD’s commitment to delivering innovative AI solutions that empower radiologists and improve patient outcomes. By integrating iCAD’s ProFound AI Breast Health Suite with Koios SmartUltrasound, we are providing clinicians with a more complete, end-to-end, AI-powered approach to breast cancer screening and detection that enhances workflow efficiency and diagnostic accuracy.”
Koios SmartUltrasound is an AI-based software platform proven to accurately detect and diagnose both thyroid and breast cancers in ultrasound exams. Built using data sourced from a global network of partner sites, the technology aids physicians in quickly and accurately diagnosing disease, improving speed of interpretation, automating reporting, and reducing time to treatment, all while avoiding unnecessary surgical procedures. The increasing utilization of ultrasound in cancer detection, particularly for women with dense breast tissue, makes this innovation particularly relevant in today’s evolving healthcare landscape.
Koios and iCAD will be attending ECR 2025 (Booth: AI-27 – Hall X1) from Wednesday, February 26 to March 2, 2025, in Vienna, Austria. To request a meeting or book a demo, please visit https://www.icadmed.com/about/news-events/upcoming-tradeshows-and-meetings/ecr-2025/
About Koios Medical:
Koios Medical develops medical software to assist physicians interpreting ultrasound images and applies deep machine learning methods to the process of reaching an accurate diagnosis. The Koios DS platform uses advanced AI algorithms to assist in the early detection of disease while reducing recommendations for biopsy of benign tissue. Patented technology saves physicians time, helps improve patient outcomes, and reduces healthcare costs. Koios DS (decision support) is SmartUltrasound, presently focused on the breast and thyroid cancer diagnosis market. Women with dense breast tissue (over
About iCAD, Inc.
iCAD, Inc. (NASDAQ: ICAD) is a global leader on a mission to create a world where cancer can’t hide by providing clinically proven deep learning solutions that enable medical providers to accurately and reliably detect cancer earlier and improve patient outcomes. Headquartered in Nashua, N.H., USA, iCAD’s industry-leading ProFound Breast Health Suite provides AI-powered mammography analysis for breast cancer detection, density assessment and risk evaluation. Used by thousands of providers serving millions of patients, ProFound is available in over 50 countries. In the last five years alone, iCAD estimates reading more than 40 million mammograms worldwide, with nearly
Forward-Looking Statements
Certain statements contained in this News Release constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements about the expansion of access to the Company’s products, improvement of performance, acceleration of adoption, expected benefits of ProFound AI®, the benefits of the Company’s products, and future prospects for the Company’s technology platforms and products. Such forward-looking statements involve a number of known and unknown risks, uncertainties, and other factors that may cause the actual results, performance, or achievements of the Company to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. Such factors include, but are not limited, to the Company’s ability to achieve business and strategic objectives, the willingness of patients to undergo mammography screening, whether mammography screening will be treated as an essential procedure, whether ProFound AI will improve reading efficiency, improve specificity and sensitivity, reduce false positives and otherwise prove to be more beneficial for patients and clinicians, the impact of supply and manufacturing constraints or difficulties on our ability to fulfill our orders, uncertainty of future sales levels, to defend itself in litigation matters, protection of patents and other proprietary rights, product market acceptance, possible technological obsolescence of products, increased competition, government regulation, changes in Medicare or other reimbursement policies, risks relating to our existing and future debt obligations, competitive factors, the effects of a decline in the economy or markets served by the Company; and other risks detailed in the Company’s filings with the Securities and Exchange Commission. The words “believe,” “demonstrate,” “intend,” “expect,” “estimate,” “will,” “continue,” “anticipate,” “likely,” “seek,” and similar expressions identify forward-looking statements. Readers are cautioned not to place undue reliance on those forward-looking statements, which speak only as of the date the statement was made. The Company is under no obligation to provide any updates to any information contained in this release. For additional disclosure regarding these and other risks faced by iCAD, please see the disclosure contained in our public filings with the Securities and Exchange Commission, available on the Investors section of our website at https://www.icadmed.com and on the SEC’s website at http://www.sec.gov.
CONTACTS
iCAD Media Inquiries:
pr@icadmed.com
iCAD Investor Inquiries:
John Nesbett/Rosalyn Christian
IMS Investor Relations
icad@imsinvestorrelations.com
Koios Inquiries:
Media Contacts:
Tonja Haugh
thaugh@koiosmedical.com
(716) 574-2165
FAQ
What is the purpose of the iCAD and Koios Medical partnership announced in February 2025?
How does Koios SmartUltrasound technology benefit breast cancer detection?
Where and when will iCAD (ICAD) showcase their new integrated AI solution?
What specific AI technologies are being integrated in this ICAD partnership?
